source
- J&J touts promising RIPTAC data with 59% PSA reductions in prostate cancer trialAt the European Society for Medical Oncology (ESMO) 2026 meeting in Madrid, Johnson & Johnson presented early clinical data from its RIPTAC platform, which the company acquired through a $3 billion…
- Akeso reports survival benefit for ivonescimab in China-only biliary tract cancer trial, likening results to KeytrudaAkeso announced new data from a late‑stage study of its PD‑1×VEGF bispecific antibody ivonescimab in patients with biliary tract cancer enrolled only in China. The trial showed an improvement in o…Endpoints · 16d agoPositive readoutPositive